Categories: News

F-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, announced today that the Company will hold a conference call and webcast on March 14, 2022, at 9:00 a.m. EST to review fourth quarter and full-year 2021 financial results and provide a corporate update.

To access the call, participants may join via a live webcast on the Investors and News section of the F-star Therapeutics website, under Events and Presentations. To join by phone, participants may dial the following numbers at least 10 minutes prior to the start of the call:

US/Canada: 1-833-471-0868
International: 1-914-987-7751
United Kingdom: 800 0288438 or 0203 1070289

A replay of the conference call will be available for 90 days from the call and may be accessed in the Investors & News/Events and Presentations section on the F-star Therapeutics website.

About F-star Therapeutics, Inc.

F-star Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer. F-star is pioneering the use of tetravalent (2+2) bispecific antibodies to create a paradigm shift in cancer therapy. The Company has four second-generation immuno-oncology therapeutics in the clinic, each directed against some of the most promising IO targets in drug development, including LAG-3 and CD137. F-star’s proprietary antibody discovery platform is protected by an extensive intellectual property estate. F-star has over 500 granted patents and pending patent applications relating to its platform technology and product pipeline. The Company has attracted multiple partnerships with biopharma targeting significant unmet needs across several disease areas, including oncology, immunology, and CNS.

For more information visit our website and follow us on LinkedIn and Twitter.

For further information, please contact:

For investor inquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@fstar.com

John Fraunces
Managing Director
LifeSci Advisors LLC
+1 917 355 2395
jfraunces@lifesciadvisors.com

For media inquiries
Helen Shik
Shik Communications LLC
+1 617-510-4373
helen@shikcommunications.com 

Staff

Recent Posts

Back Pain, Prostatitis, Enlarged Prostate (BPH) and Kidney Stones are Treated with the Safest Thermobalancing Therapy

The first safe therapy with Dr Allen's Device has once again proved its ability to…

3 hours ago

Defence Completes 2nd Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB:…

23 hours ago

Masimo Corporation Board of Directors Authorizes Management to Evaluate the Separation of Consumer Business

IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products,…

24 hours ago

Axonics Stockholders Approve Merger Agreement with Boston Scientific

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) announced that its stockholders have voted today to adopt…

24 hours ago

Pramana Achieves Industry-Leading Milestone with Digital Pathology 2.0 Technology

Over 6.5 Million Glass Slides Digitized in the Last 12 Months and 15 Billion Images…

24 hours ago